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Abstract
Objective: Flow cytometry is becoming an important tool in the charac-
terization of different hematological disorders. The aim of our study was 
to detect very rare populations in hematological malignancies using the 
comprehensive concept of immunophenotyping.
Patients and Methods: Six patients, including three with acute myeloid 
leukemia, one with acute lymphoblastic leukemia, one with myelodysplas-
tic syndrome, and one with B-cell lymphoma, were enrolled in this study. 
Serial bone marrow aspirates were analyzed by three-color multidimen-
sional flow cytometry.
Results: The core principles for the use of flow cytometric analysis are 
understanding deviations in abnormal antigen expression from normal 
cellular differentiating pathways and characterizing different patterns of 
antigenic aberrancy for each patient. Our results demonstrate that multi-
dimensional flow cytometry can be used to: (1) monitor minimal residual 
disease after treatment; (2) aid in the differential diagnosis of cases, which 
are difficult to evaluate using conventional morphology; and (3) help in 
the staging of lymphoproliferative disorders.
Conclusion: After selecting appropriate combinations of monoclonal anti-
bodies, and applying advanced knowledge in immunophenotyping, flow 
cytometry is very sensitive and specific for the detection of rare populations 
in hematological disorders. [Tzu Chi Med J 2009;21(1):40–51]
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1. Introduction
Analysis of human bone marrow aspirates is compli-
cated by the presence of multiple cell lineages, each 
of which are at a variety of maturational stages. 
Traditionally, microscopic examination can be used 
to identify most hematological disorders. However, it 
is difficult to discriminate very rare populations of 
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abnormal cells from a heterogeneous marrow envi-
ronment. For example, patients with fewer than 5% 
morphologically identifiable blasts in bone marrow 
samples are judged to be in hematological remission, 
although they may still harbor as many as 1011–1012 
leukemic cells. The use of polymerase chain reaction 
to identify fusion transcripts and clonal antigen-receptor 
gene rearrangements is attractive because of its high 
sensitivity of one target cell per 103–106 cells. However, 
only a minority of hematological diseases have spe-
cific genetic abnormalities available for clinical uses.
Immunophenotyping has become a powerful tool 
for characterizing different kinds of hematological dis-
orders including acute and chronic leukemias, lym-
phoproliferative disorders, and paroxysmal nocturnal 
hemoglobulinemia. Immunophenotyping can even aid 
as an adjunct in the diagnosis of myelodysplastic syn-
drome (MDS) and other myeloproliferative disorders. 
It has been shown that maturation of myeloid and lym-
phoid cells can be assessed by multidimensional flow 
cytometry [1–3]. This technique permits the identi-
fication of cellular lineage and maturational stage 
in heterogeneous cell populations, and allows the de-
tection of potential deviations from normal cellular 
differentiating pathways [4–7].
The development of multidimensional flow cytom-
etry has increased the sensitivity and specificity for 
the detection of minimal residual hematological ma-
lignancies after treatment. The concept of minimal 
residual disease (MRD) was introduced to more ac-
curately estimate the true number of malignant cells 
and, in turn, to improve clinical management and cura-
tive rates. There is evidence that the presence of 
MRD significantly increases the rate of relapse and 
reduces overall survival for acute myeloid leukemia 
(AML) [8–11] and acute lymphoblastic leukemia (ALL) 
[12–14].
Here, we describe this comprehensive concept of 
multidimensional high resolution flow cytometry by 
the demonstration of six patients with various hema-
tological diseases. The three goals of this study were: 
(1) to detect minimal residual disease after treatment; 
(2) to aid in the initial differential diagnosis of cases, 
which are difficult to evaluate using conventional mor-
phology; and (3) to help in the staging of lymphopro-
liferative disorders.
2. Patients and methods
2.1. Patients
Six patients with various hematological disorders were 
enrolled in this analysis. Diagnostic bone marrow was 
obtained for morphological evaluation, cytogenetic 
study and flow cytometric analysis. Serial follow-up 
bone marrow aspirates for those patients who received 
treatment were also sent for analysis. All six patients 
signed informed consent to undergo bone marrow 
examination and flow cytometric tests.
2.2. Cell preparation and multidimensional 
flow cytometric analysis
The procedure for labeling cells has been previously 
described [15]. A working dilution of monoclonal an-
tibodies titered for maximum fluorescence, CD45 
peridinin-chlorophyll-a protein (CD45 PerCP), and 
0.1 mL of well-mixed heparinized bone marrow were 
incubated for 20 minutes at room temperature in 
the dark. The erythrocytes were lysed by adding 3 mL 
NH4Cl (0.83%, buffered with KHCO3, pH 7.2) for 
5 minutes at 37°C. The cells were then pelleted, 
washed twice in phosphate buffered saline (PBS), 
pelleted again and re-suspended in PBS with 1% 
paraformaldehyde.
Specimens were analyzed on a FACSCalibur (Becton 
Dickinson Immunocytometry Systems, San Jose, CA, 
USA) flow cytometer. The three color fluorescence 
used for monoclonal antibody conjugate included 
peridinin-chlorophyll-a protein (PerCP), phycoerythrin 
(PE), and fluorescein isothiocyanate (FITC). The instru-
ment set-up was first standardized using lymphocytes 
as a reference, which was accomplished by gating on 
the unstained lymphocytes. This was followed by ad-
justment of the light scattering detectors to place the 
lymphocytes in a standard position in the correlative 
display of forward light scattering and orthogonal light 
scattering. Lymphocytes and maturing myeloid cells 
were then stained for further standardization using a 
series of fluorescence-conjugated monoclonal anti-
bodies, which included CD45-PerCP, CD4-FITC and 
CD8-PE for lymphocytes and CD45-PerCP, CD11b-PE 
and CD16-FITC for myeloid cells.
For each combination of antibodies, a total of at 
least 10,000 events were recorded. List mode data 
were analyzed with WinList software (Verity Software, 
Tospsham, ME, USA) in accordance with previously 
published techniques [15–17]. For each sample, a 
computerized region was created to limit the analy-
sis to viable cells with a forward and right-angle light 
scatter pattern characteristic of lymphocytes, mono-
cytes, maturing myeloid elements, and blast-sized 
cells. Secondary gating was performed to limit further 
analysis to different groups of cells based on charac-
teristic CD45 versus log side scatter properties.
Monoclonal antibodies used in this study were ob-
tained from the indicated sources: fluorescein iso-
thiocyanate (FITC-conjugated): CD16 from Pharmingen 
International (San Jose, CA, USA); CD14, CD15, 
CD33, CD34, CD7, CD5, CD38, HLA-DR, CD3, CD5, 
CD56, CD20, CD4, CD22, FMC-7, kappa, lambda, CD2 
from Becton Dickinson Immunocytometry Systems 
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(San Jose, CA, USA). Phycoerythrin (PE-conjugated): 
CD11b, CD13, CD33, CD14, CD19, CD34, CD56, CD38, 
CD5, CD23, CD8, CD25 from Becton Dickinson; CD10 
from Pharmingen International; peridinin-chlorophyll-a 
(PerCP-conjugated) CD45 from Becton Dickinson.
Fig. 1 shows an example of the normal matura-
tional pathway for the myeloid elements.
3. Results
3.1. Detection of minimal residual disease 
after treatment
Case 1 was a woman aged 40 years with acute mye-
loid leukemia. Diagnostic flow cytometry of her bone 
marrow aspirate demonstrated 22.5% blasts. As shown 
in Fig. 2, the leukemic blasts revealed intermediate 
signals on side scatter and forward scatter. The blasts 
had low expression of CD45 but had high expression 
of CD34, HLA-DR, CD13 and CD33. Of importance, 
aberrant CD19 expression was found at a high level. 
Cytochemical staining of myeloperoxidase was also 
positive on the morphological examination. This was 
classical AML with aberrant CD19 expression. After in-
duction chemotherapy with 3 days of idarubicin plus 
7 days of Ara-C (I3A7), the blasts remained at 14.0% 
on day 16. Additional chemotherapy with 2 days of 
mitoxantrone and 5 days of Ara-C (N2A5) was given 
immediately. Nineteen days later, flow cytometric anal-
ysis revealed almost no residual leukemia based on the 
gating of CD19. Because complete remission was suc-
cessfully achieved, consolidation chemotherapy with 
high-dose Ara-C (HD-AC) was given. Unfortu nately, after 
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Fig. 1 — Development of myeloid cells during normal hematopoiesis. Myeloid elements and monocytes are both shown 
in green. Four populations of lymphocytes, monocytes, maturing myeloid elements and blasts can be clearly identified 
based on different characteristics among CD45, and forward and side light scatters. On the panel of CD11b vs. HLA-DR, 
promyelocytes show very low expression of both antigens. During the process of differentiation toward neutrophils, 
HLA-DR is entirely lost, but more and more CD11b is acquired. On the panel of CD13 vs. CD16, CD13 is initially shown 
on promyelocytes but it is decreased to the lowest level on myelocytes. In the later stages of development toward neu-
trophils, the intensity of CD13 and CD16 increase to maximal levels, which creates a characteristic picture of a 
“concave”-shaped maturation pathway. Monocytes are both CD11b/HLA-DR and CD13/CD16 positive. FSC = forward 
light scatter; Lymph = lymphocytes; Mono = monocytes; Myel = maturing myeloid elements; Promye = promyelocytes; 
Mye = myelocytes; Meta = metamyelocytes; Neu = neutrophils.
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recovery of the bone marrow cells, flow cytometry 
showed a small population of blasts that co-expressed 
CD33 and CD19 at only 0.3%, which indicated early 
relapse of AML. This patient then received allogeneic 
peripheral blood stem cell transplantation from her 
sibling. As shown in Fig. 3, on the day of stable engraft-
ment, flow cytometry showed no leukemic blasts out 
of 200,000 marrow cells, which were analyzed in cor-
relation with the previous blast region based on CD33/
CD19 gating.
Case 2 was a woman aged 45 with acute promyelo-
cytic leukemia (APL). Bone marrow morphology showed 
characteristics of hypergranular promyelocytes with 
multiple intra-cytoplasmic Auer rods. A cytogenetics 
study showed classical t(15;17). Diagnostic flow cy-
tometry, as shown in Fig. 4, revealed abnormal leuke-
mic cells located between the usual blast and maturing 
myeloid region. There was a marked increase in the 
signal on the side scatter, which indicated its hyper-
granular nature. The leukemic cells showed autofluo-
rescence, high CD13 and CD33 expression and a 
lack of CD34 and HLA-DR, typical features of promy-
elocytes. The aberrant loss of CD15 expression also 
indicated its dysregulated nature. She was treated with 
standard all-trans-retinoic-acid (ATRA) plus idarubicin 
for 3 days. Complete remission was achieved with 
normalization of morphology, flow cytometry and cy-
togenetics. She was given one course of consolidation 
chemotherapy with daunorubicin. Just before the next 
cycle of consolidation chemotherapy, follow-up flow cy-
tometry showed a 4.2% abnormal population of cells 
that were located close to the usual blast region, 
although the other maturing myeloid cells showed 
orderly differentiation. These were not normal blasts 
because they did not express HLA-DR or CD34. As 
shown in Fig. 5, only several dots of normal blasts ex-
pressed CD34 and HLA-DR. These abnormal cells also 
highly expressed CD13 and CD33, indicating early 
relapse of promyelocytic leukemia. After carefully re-
viewing the bone marrow morphology, a small area 
of blast-like promyelocytes aggregates could be seen, 
which was correlated to reduced granularity on the re-
lapsed flow cytometric figure. A subsequent cytoge-
netics study confirmed re-emergence of t(15;17). 
After salvage treatment with arsenic trioxide, the small 
population of relapsed leukemic cells disappeared 
completely on flow cytometric monitoring.
Case 3 was a woman aged 54 with acute myeloid 
leukemia. As shown in Fig. 6, diagnostic flow cytom-
etry revealed 94.0% blasts with decreased CD45 and 
side scatter signals. The leukemic cells revealed high 
CD13 and CD33 expression but a lack of CD34 and 
HLA-DR (CD13 and CD34 are not shown in the figure). 
One striking feature is that the blasts aberrantly 
expressed high amounts of CD56. A follow-up bone 
marrow examination was performed 25 days after 
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Fig. 2 — Case 1: A woman aged 40 years with AML. Diagnostic flow cytometry shows 22.5% blasts, which showed low 
CD45+, CD34+, CD13+ and CD33+, and aberrantly high levels of CD19.
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induction chemotherapy. Although morphological re-
mission was achieved, minimal residual disease with 
1.2% leukemic blasts was clearly demonstrated on 
the flow cytometry. The key clues were a small popu-
lation of blasts which had aberrantly lost HLA-DR and 
CD34 expression. Again, both HLA-DR and CD34 are 
universally expressed by normally recovering myelo-
blasts or lymphoblasts. In addition, the same popula-
tion of leukemic cells revealed high CD56 expression, 
as at diagnosis. All residual leukemia was gone after 
re-induction chemotherapy.
3.2. Multidimensional flow cytometric 
analysis as an aid in initial 
differential diagnosis of cases 
which are difficult to evaluate by 
conventional morphology
Case 4 was a boy aged 15 years with a presentation 
of fever and chills. Extreme leukocytosis was found 
in the peripheral blood circulation. Bone marrow ex-
amination revealed leukemic marrow. The blasts were 
intermediate in size with multiple intra-cytoplasmic 
vacuolizations, as shown in Fig. 7. These findings 
raised concerns of Burkitt’s leukemia, a mature B-cell 
leukemia. Some specific chemotherapeutic regimens 
should be chosen for Burkitt’s leukemia rather than 
for non-Burkitt’s leukemia. As shown in Fig. 8, the im-
mediate flow cytometry revealed that the leukemic 
blasts showed markedly decreased CD45 expression, 
a striking feature of acute lymphoblastic leukemia. 
The enhanced CD19 expression indicated its B-cell 
origin. The lack of clonal immunoglobulin light chain 
expression on the panels of CD19 vs. kappa and CD19 
vs. lambda definitely excluded the possibility of ma-
ture B-cell leukemia or lymphoma. High CD10 expres-
sion was strong evidence of precursor B-cell ALL. 
Chromosome study showed t(1;19), which corresponds 
to cytogenetics for non-Burkitt’s lymphoma. Flow cyto-
metric analysis after induction chemotherapy showed 
no residual leukemic cells present on the lower CD45 
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Fig. 3 — Case 1: A woman aged 40 years with AML. Upper left & middle: Sixteen days after induction chemotherapy 
with I3A7, residual blasts are at 14.0% and express CD33 and CD19. Upper right: Nineteen days after re-induction 
chemotherapy with N2A5, no residual leukemia is seen based on CD19 gating. Lower left: Relapse of leukemia with 
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Lower right: No MRD is seen after allogeneic peripheral blood stem cell transplantation (allo-PBSCT).
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vs. higher CD19 or CD10 region, an area that is char-
acteristic of the presence of precursor B-ALL.
Case 5 was a woman aged 53 years with pancyto-
penia of an unknown cause. Bone marrow morphology 
showed hypocellular marrow. Only a few subtle 
changes were seen on the three blood cell lineages, 
which made the differential diagnosis between aplas-
tic anemia and myelodysplastic syndrome difficult. 
Flow cytometry revealed that the number of blasts 
was within the normal range at 1.4%. As shown in 
Fig. 9, the four populations of lymphocytes, mono-
cytes, maturing myeloid cells and blasts were in the 
proper positions on the side scatter vs. forward scat-
ter and the CD45 vs. side scatter panels. However, a 
small but significant portion of CD56 is aberrantly 
expressed on blasts, monocytes and maturing myeloid 
elements. This condition is consistent with aberrant 
antigen expression of myelodysplasia. A cytogenetics 
study showed complex chromosome changes that 
confirmed the flow cytometric diagnosis of myelo-
dysplastic syndrome.
3.3. Help in the staging of 
lymphoproliferative disorders
Case 6 was a man aged 66 years with MALToma of the 
left lacrimal gland. Endoscopic examination of the 
stomach revealed no gastric MALToma. A whole-body 
computed tomography scan showed no involvement 
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Fig. 7 — Case 4: A boy aged 15 years with ALL. Diagnostic 
bone marrow tests show that the leukemic blasts are 
intermediate in size with multiple intra-cytoplasmic vacu-
olizations, findings with which it is difficult to differenti-
ate between Burkitt’s and non-Burkitt’s leukemia.
 TZU CHI MED J  March 2009  Vol 21  No 1 47
of lymphoma in the visceral organs or other lymphoid 
structures. A bone marrow examination was performed 
for morphological survey. The marrow aspirate did 
not show any abnormal aggregates of lymphocytes. 
The pathology of the biopsy sample revealed a few 
suspicious areas that may have had lymphoma involve-
ment, as shown in Fig. 10A. Careful examination of 
the flow cytometric analysis of the bone marrow as-
pirate revealed a small population of lymphocytes at 
7.0% that showed low CD45 expression on the CD45 
vs. side scatter panel. As shown in Fig. 11, these cells 
were smaller and less granular than normal T-cells. 
These lymphocytes revealed high CD19 expression 
with clonal surface kappa expression. CD5 was neg-
ative, which excluded chronic lymphocytic leukemia 
and mantle cell lymphoma. CD10 was negative, which 
excluded follicular center B-cell lymphoma. They were 
small in size, which excluded large B-cell lymphoma. 
Other markers showed CD20+, HLA-DR+ and sub-
populations of CD23+, CD22+, and FMC-7+. All flow 
cytometric data were consistent with marginal zone 
origin of B-cell lymphoma, which was in accordance 
with MALToma involvement in the bone marrow. A cy-
tochemical L-26 (CD20) stain of the marrow biopsy 
sample also confirmed the involvement of B-cell lym-
phoma, as shown in Fig. 10B.
4. Discussion
Our current study shows that multidimensional flow 
cytometry is a very sensitive and specific tool in the 
diagnosis of hematological disorders and for the 
monitoring of minimal residual disease after treat-
ment. It aids the selection of a specific therapeutic 
strategy for individual patients. To apply this highly 
sophisticated flow cytometry method, one should 
first be aware of the normal maturation pathways of 
blood cells demonstrated on flow cytometric figures. 
The normal myeloid and lymphoid cellular differenti-
ation in bone marrow has been extensively studied 
using flow cytometry [1–3]. Second, it is necessary 
to carefully compare the deviations in various hema-
tological disorders from the normal cellular differen-
tiating pathways on flow cytometry [4–7]. Thus the 
most important figures shown by multidimensional 
flow cytometry are to characterize the different “pat-
terns” between normal and abnormal cells, but not 
just to quantify the expression of one specific sur-
face antigen. After applying these core principles of 
immunophenotyping, various hematological disor-
ders can be illustrated clearly.
Using multidimensional flow cytometry for these 
six unique cases, we were able to demonstrate our 
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three goals, as follows: (1) detection of minimal re-
sidual disease after treatment; (2) aid in initial differ-
ential diagnosis of cases which are difficult to evaluate 
by conventional morphology; (3) help in the staging 
of lymphoproliferative disorders.
Cases 1–3 are characteristic examples of the de-
tection of MRD in patients with AML. As described in 
previous studies, there are four types of aberrant 
antigen expression on myeloid leukemic cells: (1) ex-
pression of non-myeloid antigens; (2) asynchronous 
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Fig. 10 — Case 6: A man aged 66 years with MALToma of the left lacrimal gland. (A) A bone marrow biopsy with 
hematoxylin-eosin staining shows a few suspicious small lymphoid aggregates. (B) L-26 staining (brown) confirms 
interstitial involvement of B-cell lymphoma.
 TZU CHI MED J  March 2009  Vol 21  No 1 49
Blast Myel
Lymph
Mono
100
103
102
101
100
101
C
D
4
5
 P
er
C
P
SSC-height
102 103
Ab_Lym
100
103
104104104
104104
102
101
100
101
C
D
1
9
 P
E
CD5 FITC
102 1030 200 400 600 800 1000
103
102
101
100
S
S
C
-h
ei
g
h
t
FSC-height
10 11
12 13
100
103
104
104
102
101
100
101
C
D
1
1
b
 P
E
Anti-HLA-DR FITC
102 103
6 7
8 9
C
D
2
5
 P
E
100
103
104
104
102
101
100
101
CD22 FITC
102 103
6 7
8 9
Lymph
100
103
104
104
102
101
100
101
C
D
1
9
 P
E
CD5 FITC
102 103
6 7
8 9
Blast
100
103
104
104
102
101
100
101
C
D
2
3
 P
E
FL1-height
102 103
6 7
8 9
Blast
100
103
104
104
102
101
100
101
C
D
1
0
 P
E
CD20 FITC
102 103
6 7
8 9
Blast
C
D
1
0
 P
E
100
103
104
104
102
101
100
101
CD20 FITC
102 103
10 11
12 13
Lymph
100
103
104
104
102
101
100
101
C
D
1
9
 P
E
FMC7 FITC
102 103
6 7
8 9
Blast
100
103
104
104
102
101
100
101
C
D
1
9
 P
E
Kappa FITC
102 103
6 7
8 9
Blast
100
103
104
104
102
101
100
101
C
D
1
9
 P
E
Lambda FITC
102 103
6 7
8 9
Blast
Fig. 11 — Case 6: A man aged 66 years with MALToma. Diagnostic flow cytometry shows 7.0% abnormal lymphocytes 
(red), which show low CD45 expression, decreases in size and granularity, enhanced CD19+, surface kappa+, lambda-, 
CD5-, CD10-, CD20+, HLA-DR+, and subpopulation of CD23+, CD22+, and FMC-7+, feature consistent with the marginal 
zone origin of B-cell lymphoma.
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expression of myeloid associated antigens; (3) over-
expression of myeloid associated antigens; and (4) 
absence of expression of myeloid associated anti-
gens [4,18]. Aberrant expression of non-myeloid an-
tigens in AML is the so-called “lineage infidelity”. AML 
expressing both lymphoid (CD2, 5, 7, 10, 19, and 25) 
or natural killer (NK) antigens (CD56) and myeloid 
(CD13, 14, 15, and 33) antigens allows the detection 
of unusual phenotypes in the presence of normal he-
matopoietic elements [4,18,19]. As shown in Cases 
1 and 3, aberrant CD19 or CD56 expression on leuke-
mic cells are key clues in monitoring MRD. Overex-
pression of myeloid associated antigens is a common 
manifestation of AML. For example, overexpression 
of CD34, HLA-DR, CD13 and CD33 was shown in 
Case 1 and enhanced CD13 and CD33 expression was 
demonstrated in Case 3. On the other hand, the ab-
sence of normal myeloid associated antigens may 
occur occasionally. CD34 and HLA-DR were aber-
rantly lost in Case 3. As mentioned above, the most 
important concept in detecting MRD is not just to 
rely on specific antigens but to view all antigenic ab-
normalities as a whole dysregulated pattern. All three 
cases with AML revealed distinct patterns of flow cy-
tometric abnormalities. For example, Case 2 had 
acute promyelocytic leukemia. The diagnostic flow 
cytometric abnormalities showed a characteristic 
pattern of autofluorescence, hypergranularity, en-
hanced CD13, and CD33 and a lack of CD34 and 
HLA-DR, which was accompanied by aberrant loss of 
CD15 expression on the leukemic cells. This pattern 
of abnormality is so distinct that it allowed for the 
detection of a very rare population of MRD during sub-
sequent follow-up. The potential benefit of detecting 
MRD during continuing chemotherapy is that it pre-
dicts the likelihood of subsequent relapse. It may 
therefore facilitate dose intensification and strate-
gies such as stem cell transplantation, as shown in 
our patients.
Flow cytometry can also lead to a very rapid and 
specific diagnosis in cases that are difficult to evalu-
ate with conventional morphology. Case 4 is such an 
example. Acute lymphoblastic leukemia was readily 
observed based on morphological findings. However, 
the presence of multiple intra-cytoplasmic vacuoliza-
tions raised concerns of Burkitt’s leukemia. Unlike a 
time-consuming cytogenetics study, multidimensional 
flow cytometric analysis immediately confirmed this 
was precursor B-cell ALL and excluded the possibility 
of Burkitt’s type leukemia because no clonal immu-
noglobulin light chain expression was found on the 
surface of the leukemic cells. This rapid and accurate 
diagnosis helped the clinical physician initiate appro-
priate treatment planning quickly. Again, after consid-
ering the abnormal antigen expression as a complete 
pattern, MRD was undetectable in this patient after 
induction chemotherapy.
Myelodysplastic syndromes are another complex 
and heterogeneous group of hematopoietic stem cell 
disorders that are sometimes difficult to evaluate 
morphologically. Flow cytometric analysis is especially 
useful in the evaluation of myelodysplasia. With the 
understanding of normal antigenic expression during 
hematopoietic development, the dysregulation of he-
matopoiesis in MDS could be characterized based on 
deviations from the normal patterns of antigenic ex-
pression demonstrated on multidimensional flow cy-
tometry [3,20–23]. Immunophenotypic abnormalities 
can be observed on myeloblasts and on maturing 
cells. Case 5 is an example in which MDS was recog-
nized by the aberrant CD56 expression on blasts, 
monocytes and maturing myeloid elements. Wells 
et al also established a new flow cytometric scoring 
system in the analysis of myelodysplastic syndrome 
correlated with the results of the International Prog-
nostic Scoring System (IPSS) and can predict outcome 
significantly [20].
The staging work-up for lymphoproliferative disor-
ders is very important because treatment planning 
may differ for different stages of disease. Bone marrow 
examination is essential to define stage IV disease, 
which is conventionally evaluated by morphological 
interpretation. However, it may miss very rare in-
stances of bone marrow involvement. In this situa-
tion, multidimensional flow cytometry can provide a 
rapid, sensitive and specific evaluation, as shown in 
Case 6. Although as few as 7.0% of lymphoma cells 
are involved in the bone marrow, flow cytometric 
analysis clearly revealed a group of clonal marginal 
zone B-cell lymphoma, which was difficult to view on 
conventional morphological examination.
In this article, with the demonstration of six 
unique cases, we showed that multidimensional flow 
cytometry is a powerful tool in the sensitivity and 
specificity in diagnosis, and for monitoring and char-
acterization of different hematological disorders. By 
using the concept of a “pattern” for flow cytometry 
and recognizing any differences between normal 
and aberrant flow cytometric patterns, even very 
rare populations of abnormalities can be identified 
clearly. This may help to optimize subsequent treat-
ment strategies, and will benefit the individual 
patient.
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